LifeStance Health Group (NASDAQ:LFST) Stock: Insider Ryan Pardo Sells 2,216,585 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) insider Ryan Pardo sold 2,216,585 shares of LifeStance Health Group stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $14.58, for a total transaction of $32,317,809.30. Following the sale, the insider owned 334,935 shares in the company, valued at $4,883,352.30. This represents a 86.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ryan Pardo also recently made the following trade(s):

• On Tuesday, November 10th, Ryan Pardo sold 587,920 shares of LifeStance Health Group stock. The stock was sold at an average price of $14.58, for a total transaction of $8,571,873.60.

LifeStance Health Group Price Performance

LFST traded down $0.07 during midday trading on Friday, reaching $14.08. 3,728,905 shares of the company’s stock were exchanged, compared to its average volume of 6,598,220. The firm has a market capitalization of $5.35 billion, a price-to-earnings ratio of 74.11 and a beta of 1.35. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.17. LifeStance Health Group, Inc. has a one year low of $6.01 and a one year high of $15.66. The business has a 50-day simple moving average of $12.79 and a two-hundred day simple moving average of $9.67.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The company had revenue of $455.86 million for the quarter, compared to analyst estimates of $431.59 million. The firm’s quarterly revenue was up 25.3% on a year-over-year basis. As a group, research analysts predict that LifeStance Health Group, Inc. will post 0.18 EPS for the current year.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. KBC Group NV bought a new stake in shares of LifeStance Health Group during the first quarter worth $29,000. IFP Advisors Inc raised its holdings in shares of LifeStance Health Group by 316.5% in the second quarter. IFP Advisors Inc now owns 3,694 shares of the company’s stock valued at $40,000 after buying an additional 2,807 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of LifeStance Health Group by 359.1% in the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after buying an additional 5,404 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in LifeStance Health Group by 615.3% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock worth $59,000 after buying an additional 7,987 shares in the last quarter. Finally, Assetmark Inc. lifted its position in LifeStance Health Group by 17.0% during the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after buying an additional 1,367 shares in the last quarter. 85.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. KeyCorp boosted their target price on shares of LifeStance Health Group from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Canaccord Genuity Group increased their target price on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. BTIG Research lifted their price target on shares of LifeStance Health Group from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Wall Street Zen lowered shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 5th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of LifeStance Health Group in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.86.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.